 The FDA has developed several strategies to help expedite the approval process for generic drugs, including leveraging modeling and simulation methods to support alternative bioequivalence approaches. These methods can provide valuable insight into the performance of generic drugs and their potential impact on patients. This article was authored by Eleftheria Tzikalizu, Condocerolam, Priyanka Ghosh, and others.